Why Is Karyopharm Therapeutics (KPTI) Stock Down -12% Today?
Key Takeaways
- Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63
- The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints
- While the combination therapy delivered a statistically significant improvement in spleen volume reduction (SVR35), the trial failed to meet its second co-primary endpoint measuring improvement in total symptom score (Abs-TSS)
- A promising overall survival signal was reported, but investors appear focused on the regulatory uncertainty created by the partial endpoint miss
- The company plans to meet with the FDA to discuss a potential supplemental NDA filing, introducing an uncertain regulatory path forward
- Traders will closely watch the 8:00 a.m. ET earnings conference call and any subsequent FDA guidance commentary
Opening Summary
Karyopharm Therapeutics Inc. (KPTI) is a Newton, Massachusetts-based commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. Its lead product, XPOVIO® (selinexor), is a first-in-class oral XPO1 inhibitor currently approved in the U.S. for multiple myeloma and diffuse large B-cell lymphoma indications. Shares are falling roughly 12% in premarket trading on March 24, 2026, from the prior close of $7.63, following the release of highly anticipated topline data from the Phase 3 SENTRY trial in myelofibrosis. The market reaction reflects investor disappointment that the trial did not achieve a clean sweep of both co-primary endpoints required for a straightforward FDA approval pathway.
Phase 3 SENTRY Trial Results: A Mixed Picture
The SENTRY trial evaluated a once-weekly 60 mg dose of selinexor in combination with ruxolitinib versus placebo plus ruxolitinib in 353 JAK inhibitor-naïve myelofibrosis patients. The trial met its first co-primary endpoint convincingly: 50% of patients in the combination arm achieved spleen volume reduction of 35% or more (SVR35) at week 24, compared to 28% in the ruxolitinib-only arm (one-sided p<0.0001). However, the trial failed to meet its second co-primary endpoint — the average change in absolute total symptom score (Abs-TSS) — with both arms showing comparable symptom improvement from baseline (9.89 points vs. 10.86 points), a difference that was not statistically significant.
Why the Missed Endpoint Is Driving the Decline
In oncology drug development, failing to meet even one of two co-primary endpoints substantially complicates the path to regulatory approval, as the FDA typically requires demonstration of benefit across all pre-specified primary measures to grant standard approval. Karyopharm had positioned SENTRY as a potentially transformative program that could yield the first approved combination therapy for frontline myelofibrosis, and the market had assigned meaningful probability to a clean dual-endpoint win ahead of the readout. The inability to show statistically superior symptom control — despite superior spleen reduction — leaves the FDA dialogue uncertain, with Karyopharm now planning to discuss the "totality of the data" with regulators before committing to a supplemental NDA filing strategy.
The Silver Lining: Survival Signal and Spleen Data
Despite the headline disappointment, the trial delivered several noteworthy positive signals that may temper the selling pressure over time. The combination arm showed a hazard ratio of 0.43 for overall survival (95% CI [0.19, 1.00]), suggesting a greater than 50% reduction in risk of death compared to ruxolitinib monotherapy. Additionally, 32% of patients in the combination arm achieved ≥20% reduction in variant allele frequency (VAF) — a potential marker of disease modification — compared to 24% in the control arm. No new safety signals were identified, and the safety profile remained consistent with the known profiles of both agents individually, with nausea (57% vs. 17%) and thrombocytopenia (59% vs. 43%) being the most notable differences between arms.
Market Context and Trading Activity
KPTI's premarket volume is tracking well above its 30-day average of approximately 660 shares in the premarket session, consistent with a major binary catalyst event. The broader biotech sector has historically sold off sharply on mixed Phase 3 reads — particularly when a trial misses a co-primary endpoint — even when secondary and exploratory data offer encouraging signals. The stock had entered the data readout having already rebounded strongly from 2025 lows, with investors pricing in a significant probability of a positive outcome, amplifying the downside reaction to the partial miss. Peer oncology names focused on myelofibrosis, including those marketing competing JAK inhibitor-based regimens, are not expected to see significant sympathy moves given the indication-specific nature of this catalyst.
Trending AI Robots
For traders navigating volatile biotech events like today's KPTI data readout, Tickeron's Trending AI Robots page offers a curated selection of the platform's best-performing automated trading strategies under current market conditions. Tickeron operates hundreds of AI-powered trading bots covering thousands of tickers across equities, ETFs, and other asset classes, but only the strongest performers — ranked by recent accuracy, return metrics, and strategy consistency — are featured in this curated section. Bots vary across strategy type, holding timeframe, risk profile, and traded symbols, giving traders flexibility to find approaches suited to their individual style. Investors looking to systematically capitalize on momentum events or manage risk in volatile sessions may find it worthwhile to explore what Tickeron's trending bots are currently tracking.
What Comes Next for KPTI
The most immediate catalyst is the 8:00 a.m. ET conference call on March 24, where Karyopharm management will walk through the full SENTRY dataset, address regulatory strategy, and field analyst questions — commentary around FDA meeting timelines and sNDA filing plans will be closely scrutinized. Longer term, the company is also advancing its Phase 3 XPORT-EC-042 trial in endometrial cancer, with top-line data expected in mid-2026, which remains a separate potential value driver. Analyst expectations for KPTI will likely be reset following today's data, with price target revisions probable across the coverage universe given the altered regulatory outlook for the myelofibrosis program. Key risks include the possibility that the FDA declines to accept an sNDA based solely on the spleen endpoint, ongoing cash burn with the company expecting to fund operations into Q2 2026, and competitive dynamics in the rapidly evolving myelofibrosis treatment landscape.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
KPTI in +10.59% Uptrend, growing for three consecutive days on September 18, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where KPTI advanced for three days, in 220 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KPTI's RSI Indicator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on September 17, 2026. You may want to consider a long position or call options on KPTI as a result. In 79 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for KPTI just turned positive on August 18, 2026. Looking at past instances where KPTI's MACD turned positive, the stock continued to rise in 37 of 48 cases over the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for KPTI moved below the 200-day moving average on August 17, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KPTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for KPTI entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.202) is normal, around the industry mean (25.951). P/E Ratio (0.000) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.226) is also within normal values, averaging (436.793).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. KPTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KPTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation
Industry Biotechnology
Advertisement